



EUROPEAN
SOCIETY OF
CARDIOLOGY®

European Heart Journal

Volume 37 No. 6 February 2016

ISSUE @ A GLANCE



Improving prevention: risk scores, imaging, and PCSK9 inhibitors

T.F. Lüscher

499

CardioPulse

The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors

E. Blind, P.A. de Graeff, I. Meurs, F. Holtkamp, A. Baczynska, and H. Janssen

502

Leaders in cardiovascular medicine of today

Professor David Wood, Imperial College, London

M. Nicholls

503

Prevention of global cardiovascular disease

S. Yusuf, D. Wood, J. Ralston, and K. Srinath Reddy

505

The plunging mortality of cardiovascular disease in Israel

M. Gotsman and I. Gotsman

507

Book review

European Society of Cardiology textbook of preventive cardiology

J. Perk

509

CURRENT OPINION

The year in cardiology 2015: prevention

M.J. Chapman, S. Blankenberg, and U. Landmesser

510

Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution

M.L. Simoons and J.W. Deckers

520

REVIEW

Imaging

Intracoronary imaging of coronary atherosclerosis: validation for diagnosis, prognosis and treatment

K.C. Koskinas, G.J. Ughi, S. Windecker, G.J. Tearney, and L. Räber

524

AHA FAST TRACK CLINICAL RESEARCH

Lipids

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis

M.J. Lipinski, U. Benedetto, R.O. Escarcega, G. Biondi-Zoccai, T. Lhermusier, N.C. Baker, R. Torguson, H.B. Brewer Jr, and R. Waksman

536

FAST TRACK CLINICAL RESEARCH

Lipids

Prognostic value of PCSK9 levels in patients with acute coronary syndromes

B. Gencer, F. Montecucco, D. Nanchen, F. Carbone, R. Klingenberg, N. Vuilleumier, S. Aghlmandi, D. Heg, L. Räber, R. Auer, P. Jüni, S. Windecker, T.F. Lüscher, C.M. Matter, N. Rodondi, and F. Mach

546

CLINICAL RESEARCH

Coronary artery disease

Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events

P.M. Ridker, N. Rifai, G. Bradwin, and L. Rose

554

Prevention and epidemiology

Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history

H. Tada, O. Melander, J.Z. Louie, J.J. Catanese, C.M. Rowland, J.J. Devlin, S. Kathiresan, and D. Shiffman

561

Editorial

Family or SNPs: what counts for hereditary risk of coronary artery disease?

H. Schunkert

568

EHJ BRIEF COMMUNICATION

Heart failure/cardiomyopathy

MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart

S. Costantino, F. Paneni, T.F. Lüscher, and F. Cosentino

572

CARDIOVASCULAR FLASHLIGHTS

Radiotherapy-induced vascular damage in mammary arterial graft: correlations between optical coherence tomography and pathology

N. Amabile, A. Veugeois, K. Zannis, and C. Caussin

567

Fully integrated whole-body [^{18}F]-fludeoxyglucose positron emission tomography/magnetic resonance imaging in therapy monitoring of giant cell arteritis

I. Einspieler, K. Thürmel, and M. Eiber

576



Open Access Paper



For the podcast associated with this article, please visit <http://eurheartj.oxfordjournals.org/podcast>



Visit EHJ's mobile site
<http://m.eurheartj.oxfordjournals.org/>



www.eurheartj.org